1,227 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B Sell
Article Searches
Eli Lilly: New CEO, New Governance Analytics http://seekingalpha.com/article/3995254-eli-lilly-new-ceo-new-governance-analytics?source=feed_sector_healthcare Aug 03, 2016 - David Ricks will become Chairman of the Board and CEO of Eli Lilly in 2017 amidst a shifting but positive industry outlook.I took a look at a few more corporate governance trends including director te
Allergan Sharpens Its Focus: Completes Generic And Anda Divestitures, Next Steps http://seekingalpha.com/article/3995251-allergan-sharpens-focus-completes-generic-anda-divestitures-next-steps?source=feed_tag_long_ideas Aug 03, 2016 - Sale of generic business to Teva closed, downside risk to stock removed.Sale of Anda Distribution business for $500M.Looking forward to share buybacks, further minor divestitures and revised guidance.
CNBC's Faber: Allergan has no intrest in Biogen purchase http://seekingalpha.com/news/3199321-cnbcs-faber-allergan-intrest-biogen-purchase?source=feed_news_all Aug 03, 2016 - The report from David Faber echoes one from the network's Meg Tiffell last night, but perhaps with more conviction. As for Merck ([[MRK]] -1.4%) - also rum
Biogen's Recent Share Price Rally Explained http://seekingalpha.com/article/3995093-biogens-recent-share-price-rally-explained?source=feed_sector_healthcare Aug 03, 2016 - Biogen's Q2 was very good.Shareholder returns are strong, balance sheet is looking very good.Takeover by either Allergan or Merck is a possibility.
Celgene, Part 2: Pipeline, Perspectives And Peer Comparisons http://seekingalpha.com/article/3995094-celgene-part-2-pipeline-perspectives-peer-comparisons?source=feed_tag_editors_picks Aug 03, 2016 - CELG has a complex story, not all of which is well-understood. In Part 2 of a mini-series beginning with Q2 results, this article reviews much of the pipeline and demonstrates that there is much promi
Teva to seek growth beyond $40.5B Allergan deal, CEO says; buys Allergan U.S. distribution unit for $500M http://seekingalpha.com/news/3199288-teva-seek-growth-beyond-40_5b-allergan-deal-ceo-says-buys-allergan-u-s-distribution-unit-500m?source=feed_news_all Aug 03, 2016 - Teva Pharmaceutical ([[TEVA]] +1%) CEO Erex Vigodman tells Bloomberg that the completion of its $40.5B purchase of Allergan's ([[AGN]] +1.6%) generics unit
Biotech Daily Digest: A Buyout For Biogen? The Rally Continues. Spotlight On Ligand Pharmaceuticals http://seekingalpha.com/article/3995051-biotech-daily-digest-buyout-biogen-rally-continues-spotlight-ligand-pharmaceuticals?source=feed_tag_editors_picks Aug 03, 2016 - Biotech has continued its recent rally. A sell-off Tuesday was interrupted and reversed thanks to rumors about a possible buyout of Biogen.If this actually happens, it certainly would improve sentimen
Wall Street Breakfast: Is Crude Under $40 The New Normal? http://seekingalpha.com/article/3994997-wall-street-breakfast-crude-40-new-normal?source=feed_tag_wall_st_breakfast Aug 03, 2016 - The reversal in oil prices to $40 a barrel is rippling through equity and bond markets, reigniting concerns about deeply indebted companies and countries reliant on commodities. Should oil slice thro
Pfizer Investors Mood Dampened by Second Quarter Earnings http://www.gurufocus.com/news/433216/pfizer-investors-mood-dampened-by-second-quarter-earnings Aug 02, 2016 - Pfizer Investors Mood Dampened by Second Quarter Earnings, Stocks: PFE,HSP,AGN, release date:Aug 02, 2016
CNBC: Allergan unlikely to pursue any Biogen deal http://seekingalpha.com/news/3198979-cnbc-allergan-unlikely-pursue-biogen-deal?source=feed_news_all Aug 02, 2016 - Lumped in with Merck earlier on chatter that it would consider taking over Biogen (BIIB), Allergan (AGN) is unlikely to pursue such a deal, CNBC biotech/ph

Pages: 1...8788899091929394959697...123

<<<Page 92>